U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967389) titled 'Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity' on Feb. 25.
Brief Summary: The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:
* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?
* How do risk markers of disease change over the study in the study participants who are given semaglutides to help...